2008
DOI: 10.1016/j.bcp.2008.05.009
|View full text |Cite
|
Sign up to set email alerts
|

Characterisation of novel defective thiopurine S-methyltransferase allelic variants

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
34
0
1

Year Published

2009
2009
2023
2023

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 50 publications
(37 citation statements)
references
References 39 publications
2
34
0
1
Order By: Relevance
“…[5][6][7][8][9] Studies have shown that patients with a very low enzyme activity are at risk for severe, and sometimes fatal, myelotoxicity and patients who are TPMT heterozygous for one allele with low activity have an intermediate risk for myelotoxicity. [10][11][12][13][14] Whether other types of adverse event (AE) in IBD patients can be attributed to the TPMT polymorphism is less clear.…”
Section: Introductionmentioning
confidence: 99%
“…[5][6][7][8][9] Studies have shown that patients with a very low enzyme activity are at risk for severe, and sometimes fatal, myelotoxicity and patients who are TPMT heterozygous for one allele with low activity have an intermediate risk for myelotoxicity. [10][11][12][13][14] Whether other types of adverse event (AE) in IBD patients can be attributed to the TPMT polymorphism is less clear.…”
Section: Introductionmentioning
confidence: 99%
“…The best known recognized examples (TPMT, CYP2D6) are genetic polymorphisms of drug metabolizing enzymes which affect about 30% of all drugs [13]. TPMT activity in humans is inherited as an autosomal codominant trait [14] .…”
Section: Discussionmentioning
confidence: 99%
“…Although the precise circumstances have not been determined, deprotonization through water mediated hydrogen bonding has been proposed [9,27]. Despite the agreement between the calculated activation energy and observed reaction rates of the murine enzyme, the published kinetic parameters of human TPMT vary significantly, as does the source of protein, method of purification, choice of activity assay, reaction conditions (including choice of thiopurine substrate and reactant concentrations), use of units, and general presentation of results [24,28,29,30,31,32]. Both SAH and 6-Me MP coproducts inhibit the enzyme, albeit through different mechanisms; SAH is a potent competitive inhibitor with a K i of 0.75 µm with regard to SAM, and 6-Me MP is a non-competitive inhibitor with a K i of 560 µm with regard to 6-MP [10].…”
Section: Tpmt Catalysismentioning
confidence: 99%
“…Most of the known protein variants exhibit decreased in vivo enzyme activity towards thiopurine substrates, but the molecular causes of reduced functionality have only been investigated for a handful of protein variants (to date), namely TPMT*2 (A80P) [33], TPMT*3A (A154T/Y240C) [34,35], TPMT*3B (A154T) [34,35], TPMT*3C (Y240C) [34,35], TPMT*5 (L49S) [33], TPMT*16 (R163H) [30], TPMT*21 (L69V) [29], TPMT*24 (Q179S) [29], TPMT*25 (C212R) [29], Introduction and TPMT*31 (I204T) [31]. The variant proteins are often found to be destabilized (due to amino acid substitution), making them susceptible to proteolytic degradation by the quality control system of the cell [34,35,36], although one exception is TPMT*5, which exhibits nearly complete loss of function rather than reduced structural stability [33].…”
Section: Influencing Activity -Molecular Causesmentioning
confidence: 99%
See 1 more Smart Citation